Brightlands Health Breakfast Club presents Chondropeptix

We all have ideas, dreams and ambitions. We all strive for the best possible care, now and in the future. We learn from and with each other; we share experiences, contribute and receive knowledge.

We meet new people, get to know each other and share experiences. This is how any kind of information sharing and collaboration begins. Curious who your neighbors are? Come to our Brightlands Health Breakfast Club. During this Brightlands Health Breakfast Club, we will highlight Chondropeptix, a biotechnology company focused on cartilage research. The company focuses on stimulating cartilage regeneration in joints of patients with cartilage defects such as osteoarthritis or focal cartilage defects.

Chondropeptix is a spin-off of Maastricht University and the Maastricht University Medical Center. Chondropeptix and researchers from the Department of Orthopedic Surgery at Maastricht University are currently working on a peptide treatment for osteoarthritis.

It's called BMP7 p[63-82], and it's a peptide. A peptide that keeps cartilage cells healthy. Prof. Dr. Tim Welting, his co-investigator Dr. Marjolein Caron and their team have been working hard for years to turn this discovery into a treatment. Marjolein Caron will give an update on where we are now? And what do we still need to do?

The Brightlands Health Breakfast Club presentation will be given in English.

Program

• 08 a.m. Registration @ Bandito
• 08.30am Presentation Chondropeptix - Marjolein Caron
• 08.50 am Q&A
• 09.00 am Networking opportunities @ Bandito